ProShare Advisors
KLRS

ProShare Advisors’s Kalaris Therapeutics KLRS Stock Holding History

ProShare Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-611
Closed -$30.2K – 1977
2023
Q3 		$30.2K Buy
611
+111
+22% +$7.56K ﹤0.01% 1760
2023
Q2 		$39.1K Buy
500
+59
+13% +$5.61K ﹤0.01% 1793
2023
Q1 		$39.9K Sell
441
-68
-13% -$8.66K ﹤0.01% 1688
2022
Q4 		$60K Buy
509
+20
+4% +$3.39K ﹤0.01% 1721
2022
Q3 		$90K Buy
+489
New +$76.2K ﹤0.01% 1583
2022
Q2 		– Sell
-534
Closed -$84K – 2171
2022
Q1 		$84K Sell
534
-145
-21% -$28.9K ﹤0.01% 2062
2021
Q4 		$201K Sell
679
-90
-12% -$41.8K ﹤0.01% 2030
2021
Q3 		$443K Sell
769
-72
-9% -$33.3K ﹤0.01% 1281
2021
Q2 		$382K Buy
841
+105
+14% +$54.2K ﹤0.01% 1727
2021
Q1 		$396K Buy
736
+126
+21% +$106K ﹤0.01% 1611
2020
Q4 		$539K Buy
+610
New +$469K ﹤0.01% 1229

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

ProShare Advisors's KLRS Position: Q4 2023 in Review

ProShare Advisors sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 611 shares — an estimated $30.2K sold.

ProShare Advisors first reported a position in KLRS in Q4 2020 and held it in 11 quarters. The position peaked at $539K in Q4 2020. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • ProShare Advisors reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • ProShare Advisors sold 611 Kalaris Therapeutics shares in Q4 2023, an estimated $30.2K.
  • ProShare Advisors first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 11 quarters.
  • ProShare Advisors's Kalaris Therapeutics position peaked at $539K in Q4 2020.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on ProShare Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.